Manufacturers website after phase 3 trials on candidiasis.
Ibrexafungerp (formerly SCY-078) is the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids. It has shown activity against Aspergillus and Candida, including against multidrug-resistant (MDR) species Candida auris as well as Pneumocystis. Ibrexafungerp combines the well-established activity of glucan synthase inhibitors with the flexibility of oral and IV formulations, offering a broad use across different settings (in-patient and out-patient).
We believe that ibrexafungerp has the potential to be an essential therapy in the treatment of multiple serious fungal infections, including vulvovaginal candidiasis (VVC), invasive candidiasis, invasive aspergillosis and refractory invasive fungal infections.
Date of article/Start date of trial: 3 July 2019